December 25, 2014 5:06 PM ET

Pharmaceuticals

Company Overview of Ritter Pharmaceuticals, Inc.

Company Overview

Ritter Pharmaceuticals, Inc., a biological therapeutics company, engages in the discovery, development, and commercialization of therapeutic treatments for gastrointestinal diseases and conditions. The company focuses on gastrointestinal physiology, metabolism, and gut adaptation associated with gastrointestinal diseases, including lactose intolerance, irritable bowel syndrome, crohn's disease, and ulcerative colitis. It develops RP-G28 for the treatment of lactose intolerance. The company was founded in 2004 and is based in Los Angeles, California.

1880 Century Park East

Suite 1100

Los Angeles, CA 90067

United States

Founded in 2004

Phone:

310-203-1000

Fax:

310-919-1600

Key Executives for Ritter Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 54
Chairman of the Board and Chief Strategic Officer
Chief Business Officer
Age: 70
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Ritter Pharmaceuticals, Inc. Key Developments

Ritter Pharmaceuticals, Inc. Names Michael D. Step as Chief Executive Officer, Effective October 1, 2014

Ritter Pharmaceuticals, Inc. announced that Michael D. Step has been named chief executive officer, effective October 1, 2014. Mr. Step was appointed to the company's board of directors in 2011 and will continue to serve as a director. Andrew Ritter, the company's founder, who previously served as president and chief executive officer, will now hold the title of president while continuing as a director. Mr. Step has more than 20 years of experience in the pharmaceutical industry. For the past nine years, he was senior vice president of corporate development and a member of the executive committee of Santarus, Inc. until its sale to Salix Pharmaceuticals in January 2014. In this role, Mr. Step was responsible for leading the licensing activities for the company and the culmination of more than a dozen significant transactions. Prior to Santarus, Mr. Step served as vice president of corporate development and as executive director of commercial operations for Amylin Pharmaceuticals, where he led the licensing agreement with Eli Lilly a d Company for Byetta(R) and helped plan the commercial operation structure for Symlin(R). Earlier in his career, Mr. Step served in leadership roles in business development, commercial management and sales at Dura Pharmaceuticals, Hoffmann-La Roche and Syntex Laboratories.

Ritter Pharmaceuticals, Inc. Announces Publication of Lactose Intolerance Phase 2 Trial in Nutrition Journal

Ritter Pharmaceuticals, Inc. announced that Nutrition Journal has published the results of its phase 2 trial of RP-G28, a proprietary oligosaccharide under investigation as a potential treatment for lactose intolerance. The study manuscript entitled, 'Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial" is the first peer-reviewed presentation of the protocol, assessments and results which showed that RP-G28 dramatically reduced the pain and symptoms of lactose intolerant patients.

Ritter Pharmaceuticals, Inc. Appoints Larry Good as Chief Medical Officer; Expects to Design and Initiate its Next Phase 2 Clinical Studies of RP-G28 in Patients with Lactose Intolerance in Later 2013

Ritter Pharmaceuticals, Inc. announced the appointment of Larry I. Good, M.D., F.A.C.G. to the position of Chief Medical Officer. Dr. Good is a Fellow of the American College of Gastroenterology and has served as the Chief Physician in Gastroenterology at South Nassau Communities Hospital and Lydia E. Hall Hospital in New York. He joined Ritter Pharmaceuticals in 2012. The company expects to design and initiate its next Phase 2 clinical studies of RP-G28 in patients with lactose intolerance later 2013.

Similar Private Companies By Industry

Company Name Region
Bioserv Corporation United States
Riker Laboratories, Inc. United States
Artesian Therapeutics, Inc. United States
CEPTYR, Inc. United States
Live Clean Solutions LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ritter Pharmaceuticals, Inc., please visit www.ritterpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.